Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab with Immunotherapy in Advanced Melanoma
NCT03161756Phase 2Unknown
- Start
- Dec 2017
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab in melanoma (2 arms). Primary endpoints: Median Progression-Free Survival at 5 years and Occurrence of Grade 3 and 4 Selected Immune-related Adverse Events at 2 years. Status: unknown.
02
Drugs
denosumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03161756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161756.